Market Closed -
Euronext Paris
11:35:19 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
0.2485
EUR
|
+2.05%
|
|
-0.20%
|
+8.04%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
10.27
|
7.587
|
24.37
|
17.44
|
1.653
|
1.22
|
Enterprise Value (EV)
1 |
6.062
|
6.331
|
14.17
|
10.42
|
1.105
|
0.1405
|
P/E ratio
|
-0.38
x
|
-7.28
x
|
-1.75
x
|
-1.07
x
|
-0.09
x
|
-0.17
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
49,268,565
x
|
696,168,657
x
|
528,495,364
x
|
-
|
-
|
EV / Revenue
|
-
|
41,112,721
x
|
404,825,800
x
|
315,889,303
x
|
-
|
-
|
EV / EBITDA
|
-1.32
x
|
-1.57
x
|
-2.44
x
|
-0.78
x
|
-0.09
x
|
-0.03
x
|
EV / FCF
|
2.59
x
|
-1.06
x
|
-3.46
x
|
-1.42
x
|
-0.15
x
|
-0.04
x
|
FCF Yield
|
38.7%
|
-94.7%
|
-28.9%
|
-70.6%
|
-665%
|
-2,543%
|
Price to Book
|
-3.95
x
|
-4.12
x
|
3.43
x
|
3.86
x
|
-1.65
x
|
-13.5
x
|
Nbr of stocks (in thousands)
|
101
|
130
|
434
|
745
|
1,360
|
5,302
|
Reference price
2 |
102.0
|
58.20
|
56.20
|
23.40
|
1.216
|
0.2300
|
Announcement Date
|
4/12/19
|
4/22/20
|
4/28/21
|
4/22/22
|
4/24/23
|
4/25/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
0.154
|
0.035
|
0.033
|
-
|
-
|
EBITDA
1 |
-4.593
|
-4.044
|
-5.807
|
-13.44
|
-11.99
|
-5.593
|
EBIT
1 |
-4.616
|
-4.064
|
-5.824
|
-13.46
|
-12.01
|
-5.624
|
Operating Margin
|
-
|
-2,638.96%
|
-16,640%
|
-40,790.91%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-10.74
|
-0.86
|
-10.41
|
-14.45
|
-15.13
|
-6.734
|
Net income
1 |
-10.73
|
-0.861
|
-10.4
|
-14.45
|
-15.13
|
-6.736
|
Net margin
|
-
|
-559.09%
|
-29,728.57%
|
-43,793.94%
|
-
|
-
|
EPS
2 |
-269.8
|
-8.000
|
-32.16
|
-21.90
|
-12.86
|
-1.342
|
Free Cash Flow
1 |
2.345
|
-5.997
|
-4.091
|
-7.361
|
-7.349
|
-3.573
|
FCF margin
|
-
|
-3,894.07%
|
-11,688.21%
|
-22,305.3%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/12/19
|
4/22/20
|
4/28/21
|
4/22/22
|
4/24/23
|
4/25/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
4.2
|
1.26
|
10.2
|
7.02
|
0.55
|
1.08
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2.34
|
-6
|
-4.09
|
-7.36
|
-7.35
|
-3.57
|
ROE (net income / shareholders' equity)
|
329%
|
38.6%
|
-356%
|
-237%
|
-937%
|
860%
|
ROA (Net income/ Total Assets)
|
-106%
|
-81.3%
|
-58.8%
|
-82.4%
|
-100%
|
-90.9%
|
Assets
1 |
10.13
|
1.059
|
17.7
|
17.54
|
15.12
|
7.409
|
Book Value Per Share
2 |
-25.80
|
-14.10
|
16.40
|
6.060
|
-0.7400
|
-0.0200
|
Cash Flow per Share
2 |
42.70
|
10.60
|
21.90
|
12.70
|
2.690
|
0.1300
|
Capex
1 |
0.01
|
0.02
|
0.04
|
0.01
|
0.02
|
0.02
|
Capex / Sales
|
-
|
10.39%
|
111.43%
|
42.42%
|
-
|
-
|
Announcement Date
|
4/12/19
|
4/22/20
|
4/28/21
|
4/22/22
|
4/24/23
|
4/25/24
|
|
1st Jan change
|
Capi.
|
---|
| +8.04% | 7.61M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|